Glaukos vs Summit Therapeutics

Glaukos (GKOS), health care, and Summit Therapeutics (SMMT), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Glaukos is worth $14.4B on the stock market and Summit Therapeutics $8.5B: Glaukos is valued at 69% more. Over the past year Glaukos's share price has moved +167% and Summit Therapeutics's -29.7%.

Key facts

Glaukos market value
$14.4B
Summit Therapeutics market value
$8.5B
Glaukos revenue
$507.4MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Glaukos vs Summit Therapeutics: every measure side by side
Measure Glaukos Summit Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$14.4Bhigher$8.5Blower
Revenue$507.4M—
Earnings-$187.7Mhigher-$1.1Blower
Employees1,094higher265lower
Total assets$893.5Mhigher$751.2Mlower
Valuation
P/E——
P/S28.4—
P/B20.1higher15.1lower
Dividend yield0.00%0.00%
Profitability
Operating margin-39.3%—
Balance sheet
Net assets$656.2Mlower$658.9Mhigher
Total liabilities$237.3Mhigher$92.3Mlower
Total debt——
Cash on hand$90.8Mlower$225.3Mhigher
Price change
Today-0.67%higher-9.73%lower
1 year+167%higher-29.7%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Summit Therapeutics only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns GKOS · Who owns SMMT

Further comparisons

Learn

Questions and answers

Which is bigger, Glaukos or Summit Therapeutics?

By market value, Glaukos is the larger: $14.4B against $8.5B for Summit Therapeutics.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Glaukos and Summit Therapeutics?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold Glaukos and 1 holds Summit Therapeutics.

Cite this page

Funkfolio, “Glaukos vs Summit Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/gkos-vs-smmt

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.